In a significant response to the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC), health authorities have commenced a groundbreaking clinical trial aimed at evaluating two potential treatments. This initiative comes just six weeks following the World Health Organization’s (WHO) declaration of the outbreak as a public health emergency on 17 May. With the first patients now enrolled in the trial, there is cautious optimism that these experimental drugs could help reduce the mortality rates associated with the Bundibugyo strain of the virus.
Swift Action in the Face of Crisis
The rapid establishment of this treatment trial has been hailed as unprecedented, with researchers enrolling patients in record time during a crisis that has already claimed hundreds of lives. As of 9 July, DRC officials reported 1,792 confirmed cases and 625 fatalities attributed to the outbreak. Local residents, however, are growing increasingly anxious. Neema Haba, a mother and banana seller from Bunia, expressed her frustration: “We are being driven to the brink by this outbreak and nothing is going right. We are struggling to provide for our children.”
The current situation in Ituri province, where the outbreak is most severe, is marked by a complex interplay of health challenges and community mistrust. While approximately 75% of known contacts of infected individuals are being monitored, many frontline health workers have halted their activities due to inadequate remuneration and safety concerns. Ovide Maliabo, a driver for a burial team, described the dangerous nature of their work amidst community suspicion: “At one point, we narrowly escaped being lynched.”
Innovative Treatments Under Investigation
The clinical trial, named Partners, is investigating two drugs: remdesivir, an antiviral agent developed by Gilead Sciences, and MBP134, a monoclonal antibody engineered by Mapp Biopharmaceutical. Patients participating in the trial will be randomly assigned to receive one of the drugs, a combination of both, or standard supportive care. Both treatments have demonstrated effectiveness against the Bundibugyo virus in preclinical studies, leading researchers to hope for a significant reduction in mortality rates.
Professor Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp, who is involved in the trial, emphasised the need for human testing: “These two drugs actually have been proven to work against the Bundibugyo virus in animal models. We want to see if they can lower mortality in humans.” The Bundibugyo strain, while less lethal than the Zaire strain, still poses a serious threat, with approximately one in three infected individuals succumbing to the disease.
Community Engagement and Support
To ensure a comprehensive response to the outbreak, the trial aims to include participants of all ages, including pregnant and breastfeeding women who are often excluded from medical research. This inclusive approach reflects a growing recognition of the need to balance risk and benefit in clinical studies. “The benefit is potentially very high because you offer a potentially life-saving treatment to someone who has a very high chance of dying,” noted Liesenborghs.
The WHO has confirmed that sufficient supplies of remdesivir and MBP134 have been secured for 1,200 patients, courtesy of donations from Gilead and the US government. In addition, the trial is designed with flexibility, allowing for the inclusion of other promising treatments as they become available.
Professor Amanda Rojek, the international principal investigator for Partners at the University of Oxford, praised the swift mobilisation of resources and scientific expertise in the DRC, citing a stark contrast to the protracted response seen during the West African Ebola outbreak from 2014 to 2016.
Ongoing Challenges and Future Trials
While the Partners trial represents a beacon of hope, health experts caution that the challenges posed by the outbreak remain formidable. Prof Yap Boum, head of emergency response with the Africa Centres for Disease Control and Prevention, highlighted the importance of ongoing care and surveillance to contain the outbreak, stating, “What limits an outbreak is our capacity to provide care, our surveillance capacity, and our ability to isolate people.”
In addition to the Partners trial, another study is set to commence soon, focusing on whether administering a drug called obeldesivir to individuals who have been in contact with Bundibugyo cases can prevent the onset of illness. This second trial requires approximately $18 million to proceed, with $6 million already committed.
Why it Matters
The initiation of these clinical trials marks a crucial turning point in the fight against Ebola in the DRC. With the potential to provide life-saving treatments, these efforts not only aim to curb the immediate health crisis but also to foster greater trust and cooperation within affected communities. The successful development and deployment of effective therapies could significantly alter the trajectory of future outbreaks, offering hope to those at risk and paving the way for enhanced public health responses globally.
